All News

The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.

In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.

Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.

A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

Your daily dose of clinical news you may have missed.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.

Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.

Your daily dose of clinical news you may have missed.

The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Your daily dose of clinical news you may have missed.

New study found that patients living in urban areas were more likely to meet all aspects of key metrics of diabetes care.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Your daily dose of clinical news you may have missed.